
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co is poised for growth with its key products in multiple therapeutic areas such as oncology, cardiovascular disease, infectious diseases, and immunology, led by its blockbuster drug Keytruda. The recent results from its Phase 2 CADENCE study for Winrevair in CpcPH due to HFpEF were impressive, with potential for a doubling of peak sales. The company also has a strong pipeline and a leading position in the animal health market. However, there are risks such as unsuccessful commercialization of new products, surprise negative trial results, and potential challenges to key patents that could impact the stock. Overall, we believe Merck is well-positioned for continued earnings growth, despite the LOE for Keytruda in the future.
Bears say
Merck & Co is set to see a decline in sales for Keytruda, its primary revenue driver, and investors may not appreciate the potential for growth through alternative product lines. The company is also facing risks in its clinical trials, which could result in costly failures. However, the recent positive data for Winrevair in treating pulmonary hypertension suggests potential for growth in this market, with a projected 70% chance of success. While Merck has already committed to a Phase 3 trial, any failures or delays could hinder its revenue growth in the long term.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares